Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Proflavine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.95 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.95 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.95 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.95 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.95 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.95 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.95 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.95 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.95 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.95 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.95 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.95 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.95 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.95 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.75 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.48 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.45 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proflavine SCHEMBL664629 | 1.00 | KMT2A (0.95) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL10380090 | 1.00 | KMT2A (0.95) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL28534424 | 0.97 | KMT2A (0.90) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL27386 | 0.97 | KMT2A (1.00) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL29600097 | 0.97 | KMT2A (1.00) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL1679313 | 0.90 | KMT2A (0.86) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL28419396 | 0.88 | KMT2A (0.82) | KMT2ALMNAHTTMEN1ACHE | |
| SCHEMBL5394789 | 0.88 | KMT2A (0.82) | KMT2ALMNAHTTMEN1ACHE | |
| SCHEMBL31473182 | 0.88 | KMT2A (0.82) | KMT2ALMNAHTTMEN1ACHE | |
| Hydrochloric Acid SCHEMBL28534457 | 0.87 | HTR3A (0.92) | KMT2ALMNAHTTMEN1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115776886-A | Compounds useful in the treatment of COVID-19 | 东佩制药股份公司 | 2023-03-10 | — | — | CN | claimed |
| US-20250180952-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-06-05 | — | — | US | disclosed |
| EP-4493638-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-01-22 | — | — | EP | disclosed |
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | Bio Logic Crop Science S.L. (ES) | 2025-01-16 | — | — | US | disclosed |
| EP-4427745-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF | Bio Logic Crop Science, S.L. (ES) | 2024-09-11 | — | — | EP | disclosed |
| CN-118027412-A | Photo-alignment material | 罗利克技术有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11766364-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023174773-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| US-11634544-B2 | Photoaligning materials | Rolic Technologies AG (CH) | 2023-04-25 | — | — | US | disclosed |
| CN-115776886-A | Compounds useful in the treatment of COVID-19 | 东佩制药股份公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-1037667-B1 | PHARMACEUTICAL HYDROGEL FORMULATIONS, DRUG DELIVERY DEVICES AND METHODS | ALZA CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6553255-B1 | Use of background electrolytes to minimize flux variability during iontophoresis | ACIONT INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1037667-A1 | PHARMACEUTICAL HYDROGEL FORMULATIONS, DRUG DELIVERY DEVICES AND METHODS | ALZA CORPORATION (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6071508-A | ION EXCHANGING, NEUTRALIZATION | ALZA CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| US-6039977-A | WATER AND POLYVINYL ALCOHOL WITH DRUG TO FORM HYDROGEL FOR DRUG DELIVERY | ALZA CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
| EP-0824342-B1 | PREPARATION OF FORMULATIONS FOR ELECTROTRANSPORT DRUG DELIVERY | ALZA CORP (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999029348-A1 | PHARMACEUTICAL HYDROGEL FORMULATIONS, DRUG DELIVERY DEVICES AND METHODS | ALZA CORPORATION (US) | 1999-06-17 | — | — | WO | disclosed |
| US-5853383-A | Preparation for formulations for electrotransport drug delivery | ALZA CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0824342-A1 | PREPARATION OF FORMULATIONS FOR ELECTROTRANSPORT DRUG DELIVERY | ALZA CORPORATION (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996034597-A1 | PREPARATION OF FORMULATIONS FOR ELECTROTRANSPORT DRUG DELIVERY | ALZA CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | SARS1, ACE2, PHOSPHO1 | ACHE 563/4885CHRM2 424/4885HTR1A 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.